The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection

Qi Huang,1 Xingwen Zhang,2 Aijun Jia,2 Qi Huang,3 Yu Jiang,4 Liangyi Xie5 1Department of Pharmacy, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 2Emergency Intensive Care Unit, Hunan Provincial People’s Hospital (...

Full description

Bibliographic Details
Main Authors: Huang Q, Zhang X, Jia A, Jiang Y, Xie L
Format: Article
Language:English
Published: Dove Medical Press 2022-08-01
Series:Infection and Drug Resistance
Subjects:
Online Access:https://www.dovepress.com/the-pharmacokineticspharmacodynamics-and-neurotoxicity-of-tigecycline--peer-reviewed-fulltext-article-IDR
_version_ 1828453208768380928
author Huang Q
Zhang X
Jia A
Huang Q
Jiang Y
Xie L
author_facet Huang Q
Zhang X
Jia A
Huang Q
Jiang Y
Xie L
author_sort Huang Q
collection DOAJ
description Qi Huang,1 Xingwen Zhang,2 Aijun Jia,2 Qi Huang,3 Yu Jiang,4 Liangyi Xie5 1Department of Pharmacy, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 2Emergency Intensive Care Unit, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 3Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 4Institute of Emergency Medicine, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 5Department of Laboratory Medicine, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of ChinaCorrespondence: Qi Huang, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Jiefangxi Road N.61, Changsha, Hunan, People’s Republic of China, Tel +86-731-81866105, Email q12600073@163.comObjective: This study aimed to provide feasible suggestions for intraventricular injection of tigecycline to treat intractable Acinetobacter baumannii intracranial infections by studying its pharmacokinetics/pharmacodynamics and neurotoxicity.Methods: A simple and reliable two-dimensional high-performance liquid chromatography (2D-HPLC) method was used to determine tigecycline concentration. The pharmacokinetics (PK) of tigecycline in cerebrospinal fluid (CSF) was investigated by performing therapeutic drug monitoring (TDM). The pharmacodynamics (PD) of tigecycline was evaluated by its minimum inhibitory concentration (MIC) against XDR A. baumannii. CCK8 assay was used to evaluate the cytotoxicity of different concentrations of tigecycline effect on PC12 cells, and apoptosis assay was analyzed by flow cytometry.Results: Tigecycline retention time in 2D-HPLC was 7.636 min. The lower limit of quantitation (LLOQ) was 0.1mg/L, which met the requirements of concentration determination for TDM. The MIC50 and MIC90 values of tigecycline for A. baumannii were 2 and 4 mg/L, respectively. After a dose of 5mg tigecycline, Cmax in CSF was 37.894 mg/L which was high above the MIC values. The t1/2 of tigecycline was estimated to be 2.73 hours. Tigecycline significantly decreased cell viability as assessed and induced apoptosis of the PC12 cell. The IC50 value of PC12 cells treated with tigecycline was about 51.35 mg/L.Conclusion: Intraventricular injection of tigecycline is a promising method for treating XDR A. baumannii intracranial infection. Since a high concentration of tigecycline in CSF may have potential neurotoxicity, and the t1/2 was short, giving small doses of less than 5 mg at least twice a day may be safer and more effective. Intraventricular injection of tigecycline must be selected cautiously and best carried out under TDM.Keywords: tigecycline, intraventricular injection, XDR A. baumannii, intracranial infection, TDM
first_indexed 2024-12-11T00:04:13Z
format Article
id doaj.art-785f122d1d064b1fb5f20a37a2687483
institution Directory Open Access Journal
issn 1178-6973
language English
last_indexed 2024-12-11T00:04:13Z
publishDate 2022-08-01
publisher Dove Medical Press
record_format Article
series Infection and Drug Resistance
spelling doaj.art-785f122d1d064b1fb5f20a37a26874832022-12-22T01:28:22ZengDove Medical PressInfection and Drug Resistance1178-69732022-08-01Volume 154809481777640The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial InfectionHuang QZhang XJia AHuang QJiang YXie LQi Huang,1 Xingwen Zhang,2 Aijun Jia,2 Qi Huang,3 Yu Jiang,4 Liangyi Xie5 1Department of Pharmacy, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 2Emergency Intensive Care Unit, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 3Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 4Institute of Emergency Medicine, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of China; 5Department of Laboratory Medicine, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People’s Republic of ChinaCorrespondence: Qi Huang, Hunan Provincial People’s Hospital (The first-affiliated hospital of Hunan normal university), Jiefangxi Road N.61, Changsha, Hunan, People’s Republic of China, Tel +86-731-81866105, Email q12600073@163.comObjective: This study aimed to provide feasible suggestions for intraventricular injection of tigecycline to treat intractable Acinetobacter baumannii intracranial infections by studying its pharmacokinetics/pharmacodynamics and neurotoxicity.Methods: A simple and reliable two-dimensional high-performance liquid chromatography (2D-HPLC) method was used to determine tigecycline concentration. The pharmacokinetics (PK) of tigecycline in cerebrospinal fluid (CSF) was investigated by performing therapeutic drug monitoring (TDM). The pharmacodynamics (PD) of tigecycline was evaluated by its minimum inhibitory concentration (MIC) against XDR A. baumannii. CCK8 assay was used to evaluate the cytotoxicity of different concentrations of tigecycline effect on PC12 cells, and apoptosis assay was analyzed by flow cytometry.Results: Tigecycline retention time in 2D-HPLC was 7.636 min. The lower limit of quantitation (LLOQ) was 0.1mg/L, which met the requirements of concentration determination for TDM. The MIC50 and MIC90 values of tigecycline for A. baumannii were 2 and 4 mg/L, respectively. After a dose of 5mg tigecycline, Cmax in CSF was 37.894 mg/L which was high above the MIC values. The t1/2 of tigecycline was estimated to be 2.73 hours. Tigecycline significantly decreased cell viability as assessed and induced apoptosis of the PC12 cell. The IC50 value of PC12 cells treated with tigecycline was about 51.35 mg/L.Conclusion: Intraventricular injection of tigecycline is a promising method for treating XDR A. baumannii intracranial infection. Since a high concentration of tigecycline in CSF may have potential neurotoxicity, and the t1/2 was short, giving small doses of less than 5 mg at least twice a day may be safer and more effective. Intraventricular injection of tigecycline must be selected cautiously and best carried out under TDM.Keywords: tigecycline, intraventricular injection, XDR A. baumannii, intracranial infection, TDMhttps://www.dovepress.com/the-pharmacokineticspharmacodynamics-and-neurotoxicity-of-tigecycline--peer-reviewed-fulltext-article-IDRtigecyclineintraventricular injectionxdr a. baumanniiintracranial infectiontdm
spellingShingle Huang Q
Zhang X
Jia A
Huang Q
Jiang Y
Xie L
The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
Infection and Drug Resistance
tigecycline
intraventricular injection
xdr a. baumannii
intracranial infection
tdm
title The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
title_full The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
title_fullStr The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
title_full_unstemmed The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
title_short The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
title_sort pharmacokinetics pharmacodynamics and neurotoxicity of tigecycline intraventricular injection for the treatment of extensively drug resistant acinetobacter baumannii intracranial infection
topic tigecycline
intraventricular injection
xdr a. baumannii
intracranial infection
tdm
url https://www.dovepress.com/the-pharmacokineticspharmacodynamics-and-neurotoxicity-of-tigecycline--peer-reviewed-fulltext-article-IDR
work_keys_str_mv AT huangq thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT zhangx thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT jiaa thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT huangq thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT jiangy thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT xiel thepharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT huangq pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT zhangx pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT jiaa pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT huangq pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT jiangy pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection
AT xiel pharmacokineticspharmacodynamicsandneurotoxicityoftigecyclineintraventricularinjectionforthetreatmentofextensivelydrugresistantacinetobacterbaumanniiintracranialinfection